Ole Maaloes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 52 10
https://galecto.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Hans T. Schambye M.D., Ph.D. | Co-Founder, President, CEO & Director | 687.34k | N/A | 1966 |
Mr. Jonathan P. Freve CPA, CPA | Chief Financial Officer | 594.54k | N/A | 1978 |
Mr. Garrett Winslow Esq. | Senior VP, General Counsel & Corporate Secretary | 480.1k | N/A | 1979 |
Mr. Ulf J. Nilsson | Co-Founder | N/A | N/A | N/A |
Dr. Hakon Leffler | Co-Founder | N/A | N/A | N/A |
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder | N/A | N/A | N/A |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Galecto, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.